Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide

Although weight loss remains the primary goal for many obesity treatments, recent research presented at the American Diabetes Association 2026 Scientific Sessions suggests that the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy; Novo Nordisk) may extend far beyond the scale. A recent post-hoc analysis of the STEP UP trial (NCT05646706) has shed light on how high-dose semaglutide (7.2 mg) affects kidney function and systemic inflammation, providing a more comprehensive view of its therapeutic potential.¹

Background: The STEP UP Phase 3b Trial

The STEP UP trial was a randomized, double-blind, phase 3b study designed to evaluate the efficacy and safety of a higher weekly dose of subcutaneous semaglutide (7.2 mg) compared to the currently approved 2.4 mg dose. Conducted across 95 sites in 11 countries, the trial involved 1407 adults with obesity (body mass index ≥30 kg/m²) who did not have diabetes. Participants were assigned to receive either semaglutide 7.2 mg, 2.4 mg, or a placebo for 72 weeks alongside lifestyle interventions.²

The primary findings of the trial confirmed that the 7.2 mg dose led to superior weight loss. Specifically, participants on the 7.2 mg dose achieved a mean weight reduction of 18.7%, compared to 15.6% for those on the 2.4 mg dose and 3.9% for the placebo group. While effective, the higher dose was associated with a higher frequency of gastrointestinal adverse events (70.8% vs. 61.2% in the 2.4 mg group) and an increased incidence of dysaesthesia (22.9%).²

Preserving Renal Function in Obesity

The post-hoc analysis investigated the impact of these dosages on renal health, specifically focusing on the estimated glomerular filtration rate (eGFR). Measuring kidney function in patients undergoing significant weight loss can be complex because standard creatinine-based equations (eGFRcre) can be influenced by changes in muscle mass and body composition.¹

To address this, researchers compared eGFRcre with eGFRcre-cys, a measure utilizing both creatinine and cystatin C, which is considered unaffected by weight loss. The results revealed that although eGFRcre ratios remained similar across all groups, eGFRcre-cys significantly increased in both the semaglutide 7.2 mg and 2.4 mg groups compared to the placebo by week 72. This suggests that semaglutide may play a direct role in preserving or even improving kidney function in adults with obesity.¹

Reducing Systemic Inflammation

In addition to renal preservation, the analysis examined changes in high-sensitivity C-reactive protein (hsCRP), a key marker of systemic inflammation. Chronic inflammation is a common complication of obesity and a known driver of cardiovascular and metabolic diseases.

The analysis found that at the end of the 72-week period, participants in both semaglutide dose groups experienced significantly greater reductions in hsCRP compared to those receiving the placebo. This reduction in inflammatory markers, combined with the renal findings, indicates that semaglutide 7.2 mg not only facilitates advanced weight management but also contributes to a healthier metabolic and physiological profile by mitigating systemic inflammation.

In conclusion, the post-hoc data from the STEP UP trial suggest that the benefits of high-dose semaglutide are multi-faceted, offering promising results for renal preservation and the reduction of chronic inflammation in adults living with obesity.

REFERENCES

1. Rossing P, Jacobsen CSF, Hjelmesæth J, et al. High-dose semaglutide is associated with preservation of kidney function in people living with obesity without diabetes. Presented at: American Diabetes Association 2026 Scientific Sessions. June 5-8, 2026; New Orleans, LA.

2. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomized, controlled phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8